Interview with Melissa Thomas, Managing Director, Nycomed UK Ltd.
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the…
Nycomed UK Ltd.
Last updated: 13.02.2014
Address: Takeda House
Mercury Park
Wycombe Lane
Wooburn Green
High Wycombe
Bucks, HP10 0HH
United Kingdom
Tel: +44 (0) 1628 537 900
Web: http://www.takeda.co.uk/uk/
Company description
Nycomed is a privately owned, global, market-driven pharmaceutical company with a differentiated portfolio of branded medicines in gastroenterology, respiratory, inflammatory diseases, pain, and osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. With turnover of €3.2 billion in 2009, Nycomed is among the 25 largest pharmaceutical companies in the world and the 15th largest provider of over-the-counter medicines.
In the UK, recent years have seen a dramatic shift in the prescribing landscape. Nycomed UK recognises the need to respond to these significant changes and is committed to adapting its business model to allow it to effectively manage customers’ evolving needs. To this end Nycomed UK has recently introduced a revised model that it believes will allow it to flex and adapt to not only the whole system changes laid out in the recently published White Paper, but also the geographical differences that exist within the NHS. The new structure will provide the platform for national strategies to be implemented through the optimisation of regional opportunities by tailoring the amount and type of resource utilised at a local level as appropriate.
Products and services
Nycomed markets hospital products throughout Europe and general practitioner and over-the-counter medicines in selected European countries.
Protium> Gastroenterology> Pantoprazole
TachoSil> Tissue Management> 5.5mg fibrinogen/2.0IU thrombin/cm2
Alvesco> Respiratory> Ciclesonide
Preotact> Osteoporosisç> Parathyroid Hormone
Matrifen> Pain Management> Transdermal fentanyl patch
Interviews
Related
UK / Fastest Growing Private Pharmacos; GSK Shake-Up; Brexit Uncertainties; COVID-19 Reinfection Trial
The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma…
M&A / Jazz’s $7.2 Billion GW Pharma Deal: A Major Boost for Cannabinoid Research
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
UK / New Post-Brexit Regulatory Alliance with Australia, Canada, Singapore & Switzerland
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to…
UK-Japan FTA / Banishing UK Pharma's Brexit Blues
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed…
UK / MSD to Build USD 1.3 Billion London Research Hub in Boon for Post-Brexit Britain
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central…
Opinion / 3 Ways the UK’s Pharma Sector is Driving Innovation
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical…
News Roundup / UK Pharma May 2020
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British…
Coronavirus / GSK & Sanofi’s Unprecedented COVID-19 Vaccine Collaboration
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are…
The UK / The G7’s Hottest Life Science Investment Destination?
With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is…
Brexit / Uncertainty Still Reigns for UK Life Sciences
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British…
Biotech Funding / 2019 A Boom Year for UK Biotech, Despite Brexit Concerns
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019…
Cannabis / GW Pharma's CBD Drug Profits Soar in 2nd Quarter 2019
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019,…
